Tarr Mark J sold $21.7M of EHC

Tarr Mark J (President & CEO) sold 173,148 shares of Encompass Health Corp (EHC) at an average of $125.47 ($125.46–$126.06, $21.72M total) across 2 trades on 2026-08-10.

Original reporting
SEC EDGAR · Tarr Mark J
Published Aug 11, 2026, 6:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 6:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EHC
Neutral
low confidence
Mentioned
$EHC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EHCNeutralLow
01

Why it matters

Traders may treat the CEO’s sizable open-market sale as a sentiment factor, especially because it was not under a 10b5-1 plan, but there is no fundamental company news included.

02

Market read

A new Form 4 reports a large CEO open-market sale at roughly $125.46 to $126.06 per share.

03

What to watch

The article does not include any accompanying earnings, guidance, or operational update, and it does not state whether other executives or directors also sold around the same time.

Relevance 7/10Novelty 5/10Timing: filed 2026-08-11 after-hours; reflects insider sale executed 2026-08-10

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Encompass Health Corp.

Company-level read

Ticker impact

$EHCNeutralLow confidence
Context

Encompass Health CEO Tarr Mark J sold about 173,148 shares in open-market transactions totaling $21.7M, per a new Form 4 filing.

Expected impact

Near-term sentiment drag is possible, but follow-through depends on whether other insiders also sell and on broader earnings guidance.

Evidence & confidence

The filing discloses transaction size, price range, and that it was not under a pre-arranged 10b5-1 plan, but it provides no stated reason or company performance linkage.

Market effects

Limited read-through to the healthcare services sector; insider sales are company-specific signals without sector-wide catalysts in the text.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification, taxes, or planned liquidity needs, and insider sales often do not predict near-term fundamentals.

Key entities

  • Encompass Health Corp

    Subject of the Form 4 insider transaction disclosure.

  • Tarr Mark J

    President and CEO who sold shares totaling about $21.7M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EHCMed

Raymond James raises Encompass Health stock price target on strong results

Raymond James raised its price target for Encompass Health (EHC) to $155 from $150, citing strong Q3 results and raised guidance. The company beat EBITDA expectations for the 16th straight quarter, driven by acuity and cost control. EHC shares are near their 52-week high, up 32% in six months. Analysts like UBS, KeyBanc, and Truist also raised their price targets, noting strong EBITDA performance and positive 2027 outlook.

$EHCMedAI 8/10

KeyBanc raises Encompass Health stock price target on strong earnings

KeyBanc raised its price target for Encompass Health (NYSE:EHC) to $150 from $147, citing strong Q3 results. Core EBITDA beat estimates by 10% with 23% YoY growth, driven by acuity improvements and expense management. The company reported $1.52B EBITDA over the last 12 months. Same-store volumes grew 3.0%, with expectations of further improvement. Management is optimistic about 2027 and RCD expansion. The stock has returned 32% over six months, trading near its 52-week high of $133.75.

$EHCHigh

Truist raises Encompass Health stock price target on strong results

Truist Securities raised its price target on Encompass Health (NYSE:EHC) to $156 from $150, citing strong Q3 results. The company reported adjusted EBITDA of $1.52B and a 32% stock return over six months. Encompass Health raised its guidance despite headwinds and is expanding capacity. The stock trades near its 52-week high of $133.75, with a financial health score of 3.35 out of 5.